The role of NSAIDs in the management of postoperative ophthalmic inflammation

Drugs

Volumn 67, Issue 9, 2007, Pages 1291-1308

  Colin, Joseph ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACULAR LS; AMFENAC; ANTIINFLAMMATORY AGENT; BROMFENAC; CORTICOSTEROID; DEXAMETHASONE; DICLOFENAC; FLUOROMETHOLONE; FLURBIPROFEN; HYDROCORTISONE; INDOMETACIN; KETOROLAC; KETOROLAC TROMETAMOL; LEVOCOBASTINE; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PREDNISOLONE; PREDNISOLONE ACETATE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SUPROFEN; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; BURNING SENSATION; CATARACT; CATARACT EXTRACTION; CELL INFILTRATION; CHEMOSIS; CONJUNCTIVAL HYPEREMIA; CONVALESCENCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; ENZYME INHIBITION; ERYTHEMA; EYE INFLAMMATION; EYE INJURY; EYELID EDEMA; GASTROINTESTINAL IRRITATION; HUMAN; INCISION; KERATOLYSIS; KIDNEY DISEASE; LENS IMPLANT; MONOTHERAPY; MYDRIASIS; NONHUMAN; OPEN ANGLE GLAUCOMA; PHACOEMULSIFICATION; POSTOPERATIVE CARE; POSTOPERATIVE PAIN; PROSTAGLANDIN RELEASE; PRURITUS; PUNCTATE KERATITIS; REFRACTIVE SURGERY; RETINA MACULA CYSTOID EDEMA; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN DEFECT; SUPERINFECTION; SURGICAL INJURY; THROMBOCYTE FUNCTION; ULCER; URTICA DIOICA; WOUND HEALING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATARACT EXTRACTION; CONJUNCTIVITIS, ALLERGIC; ENDOPHTHALMITIS; HUMANS; MACULAR EDEMA, CYSTOID; PAIN; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

CYSTOIDEA;

EID: 34249934861     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767090-00004     Document Type: Review

References (118)

1. Samiy N, Foster CS. The role of non-steroidal anti-inflammatory drugs in ocular inflammation. Int Ophthalmol Clin 1996; 36: 195-206
2. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002; 42: 1-11
3. Sawa M, Masuda K. Topical indomethacin in soft cataract aspiration. Jpn Ophthalmol 1976; 20: 514-9
4. Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (II): a control study in bilateral extraction. Jpn Ophthalmol 1978; 22: 80-94
5. Miyake K, Sugiyama S, Norimatsu I. Prevention of cystoid macular edema after lens extraction by topical indomethacin (III): radioimmunoassay measurement of prostaglandins in the aqueous during and after lens extraction procedures. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1978; 209: 83-8
6. Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (I): a preliminary report. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1977; 203: 81-8
7. Koay P. The emerging roles of non-steroidal anti-inflammatory agents in ophthalmology [comment in Br J Ophthalmol 1996; 80: 1117]. Br J Ophthalmol 1996; 80: 480-5
8. Keates RH, McGowan KA. The effect of topical indomethacin ophthalmic solution in maintaining mydriasis during cataract surgery. Ann Ophthalmol 1984; 16: 1116-21
9. Keates RH, McGowan KA. Clinical trial of flurbiprofen to maintain papillary dilation during cataract surgery. Ann Ophthalmol 1984; 16: 919-21
10. Stark WJ, Fagadu WR, Stewart RH, et al. Reduction of pupillary constriction during cataract surgery using suprofen. Arch Ophthalmol 1986; 104: 364-6
11. Arshinoff S, D'Addario D, Sadler C, et al. Use of topical non-steroidal anti-inflammatory drugs in excimer laser photorefractive keratectomy. J Cataract Refract Surg 1994; 20 Suppl.: 216-22
12. Gwon A, Vaughan ER, Cheetham JK, et al. Ocufen (flurbiprofen) in the treatment of ocular pain after radial keratotomy. CLAO J 1994; 20: 131-8
13. Gaynes BI, Fiscella R. Topical non-steroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Safety 2002; 25: 233-50
14. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992; 36: 259-84
15. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimized cataract surgery patient care. Curr Med Res Opin 2005; 21: 1131-7
16. Schalnus R. Topical non-steroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003; 217: 89-98
17. Perianin A, Roch-Arveiller M, Giroiung IP, et al. In vivo effects of indomethacin and flurbiprofen on the locomotion of neutrophils elicited by immune and non-immune inflammation in the rat. Eur J Pharmacol 1985; 106: 327-33
18. Leonardi A, Busato F, Fregona I, et al. Anti-inflammatory and anti-allergic effects of ketorolac tromethamine in the conjunctival provocation model. Br J Ophthalmol 2000; 84: 1228-32
19. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003; 27: 281-91
20. Roberts CW. Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Ophthalmology 1996; 103: 636-9
21. Flach AJ. Nonsteroidal anti-inflammatory drugs. In: Tasman W, editor. Duane's foundations of clinical ophthalmology. Philadelphia (PA): Lippincott, 1994: 1-32
22. Solomon KD, Cheetham JK, DeGryse R, et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 2001; 108: 331-7
23. Lane SS, Modi SS, Lehmann RP, et al. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 2007; 33: 53-8
24. Roberts CW, Brennan KM. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol 1995; 113: 725-7
25. El-Harazi SM, Ruiz RS, Feldman RM, et al. A randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells. Ophthalmic Surg Lasers 1998; 29: 539-44
26. Alpar JJ. Diclofenac sodium phosphate ophthalmic solution following cataract extraction [abstract]. 9th Congress of European Society of Ophthalmology; 1992 May; Brussels
27. Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg 1999; 25: 699-704
28. Heier JS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000; 107: 2034-9
29. Flach AJ. Discussion: ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000; 107: 2039
30. Flach AJ, Graham J, Kruger LP, et al. Quantitative assessment of post-surgical breakdown of the blood-aqueous barrier following administration of ketorolac tromethamine solution: a double masked, paired comparison with vehicle-placebo solution study. Arch Ophthalmol 1988; 106: 344-7
31. Flach AJ, Lavelle CJ, Olander KW, et al. The effect of ketorolac 0.5% solution in reducing post-surgical inflammation following ECCE with IOL. Ophthalmology 1988; 95: 1279-84
32. Snyder RW, Siekert RW, Schwiegerling J, et al. Acular as a single agent for use as an antimiotic and anti-inflammatory in cataract surgery. J Cataract Refract Surg 2000; 26: 1225-7
33. Hsu JK, Johnston WT, Read RW, et al. Histopathology of corneal melting associated with diclofenac use after refractive surgery. J Cataract Refract Surg 2003; 29: 250-6
34. Thomson Physician Desk Reference: PDR® Electronic Library™ [online]. Available from URL: http://www.pdr.net [Accessed 2007 Apr 24]
35. Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: assessment of anti-inflammatory efficacy. Inflammation 2000; 24: 357-70
36. McGee DH, Heaton JD, Gruebbel MM, et al. Ocular effects of nepafenac ophthalmic suspension in New Zealand white rabbits undergoing partial corneal incisions [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 2648
37. Walker LM, Rice RL, Heaton JD, et al. Ocular effects of nepafenac ophthalmic suspension following three months of topical ocular administration to cynomolgus monkeys [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 2649
38. Heaton J, Hiddemen JW, Hackett RB, et al. Ocular effects of nepafenac ophthalmic suspension following six months of topical ocular administration to pigmented rabbits [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 2650
39. Ke TL, Graff G, Spellman JM, et al. Nepafenac, a unique nonsteroidal pro-drug with potential utility in the treatment of trauma-induced ocular inflammation II: in vitro bioactivation and permeation of external ocular barriers. Inflammation 2000; 24: 371-84
40. Kern TS, Miller C, Du YP, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007; 56: 373-9
41. Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 409-15
42. Stewart WC, Stewart R, Maxwell WA, et al. Preoperative and postoperative clinical evaluation of nepafenac 0.1% ophthalmic suspension for postcataract inflammation. Paper presented at American Society of Cataract and Refractive Surgery; 2005 Apr 18, Washington, DC
43. Nassaralla B, Szerenyi K, Wang XW, et al. Effect of diclofenac on corneal haze after photorefractive keratectomy in rabbits. Ophthalmology 1995; 102: 469-74
44. Kraff MC, Sanders DR, McGuigan L, et al. Inhibition of blood-aqueous humor barrier breakdown with diclofenac: a fluorophotometric study. Arch Ophthalmol 1990; 108: 380-3
45. Vickers FF, McGuigan LJB, Ford C, et al. The effect of diclofenac sodium ophthalmic solution on the treatment of postoperative inflammation [abstract]. Annual meeting for the Association for Research in Vision and Ophthalmology; 1991 Apr 28-May 3; Sarasota, Florida. Invest Ophthalmol Vis Sci 1991; 32: 793
46. Othenin-Girard P, Borruat X, Bovey E, et al. Association diclofenac-dexamethasone dans le traitement de l'inflammation postopératoire: étude prospective en double-insu. Klinische Monatsblatter Fúŕ Augenheilkunde 1992; 200: 362-6
47. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol 1999; 127: 253-9
48. Ostrov CS, Sirkin SR, Deutsh WE, et al. Ketorolac, prednisolone and dexamethasone for postoperative inflammation. Clin Ther 1997; 19: 259-72
49. Bucci FA, Evans RE, Amico LM. Comparison of ketorolac 0.5%, ketorolac 0.4%, and diclofenac 0.1% combined with prednisolone 0.1% on aqueous flare following cataract surgery [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 789
50. Flach AJ, Dolan BJ, Donahue ME, et al. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. Ophthalmology 1998; 105: 1775-9
51. Lu KL, Wee WR, Sakamoto T, et al. Comparison of in vitro antiproliferative effects of steroids and nonsteroidal antiinflammatory drugs on human keratocytes. Cornea 1995; 15: 185-90
52. Diestelhorst M, Schmidl B, Konen W, et al. Efficacy and tolerance of diclofenac sodium 0.1%, flurbiprofen 0.03% and indomethacin 1.0% in controlling postoperative inflammation. J Cataract Refract Surg 1996; 22: 788-93
53. Severin TD, Severin SL. Pseudophakic cystoid macular edema: a revised comparison of the incidence with intracapsular and extracapsular cataract extraction. Ophthal Surg 1988; 19: 116-8
54. Mentes J, Erakgun T, Afrashi F, et al. Incidence of cystoid macular edema after uncomplicated phacoemulsification. Ophthalmologica 2003; 217: 408-12
55. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002; 47 Suppl. 1: S203-18
56. Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery: the results of a meta-analysis. Ophthalmology 1998; 105: 397-405
57. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 1995; 96: 557-634
58. Nelson ML, Martidis A. Managing cystoid macular edema after cataract surgery. Curr Opin Ophthalmol 2003; 14: 39-43
59. Heier JS. Preventing post-cataract extraction CME. Ophthalmol Manage 2004; October: 63-72
60. Lindstrom RL, Dhaliwal DK, Dirks MS, et al. Clinical applications for NSAIDs in corneal disease and pre- and postoperative management. Ocul Surg News 2006 Feb 15; Suppl.: 1-26
61. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Cur Med Res Opin 2006; 22: 397-404
62. McColgin AZ, Raizman MB. Efficacy of topical voltaren in reducing the incidence of postoperative cystoid macular edema [abstract]. Invest Ophthalmol Vis Sci 1999; 40 Suppl.: 1529
63. Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 2003; 29: 2378-84
64. Mishima H, Masuda K, Miyake K. The putative role of prostaglandins in cystoid macular edema. Prog Clin Biol Res 1989; 312: 251-64
65. Miyake K, Masuda K, Shirato S, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol 2000; 44: 58-67
66. Flach AJ, Stegman RC, Graham J, et al. Prophylaxis of aphakic cystoid macular edema without corticosteroids: a paired-comparison, placebo-controlled double-masked study. Ophthalmology 1990; 97: 1253-8
67. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991; 112: 514-9
68. Weisz JM, Bressler NM, Bressler SB, et al. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology 1999; 106: 1656-9
69. Solomon KD. Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen-CME Study Group I. J Cataract Refract Surg 1995; 21: 73-81
70. Ginsburg AP, Cheetham JK, DeGryse RE, et al. Effects of flurbiprofen and indomethacin on acute cystoid macular edema after cataract surgery: functional vision and contrast sensitivity. J Cataract Refract Surg 1995; 21: 82-92
71. Miyake K, Sakamura S, Miura H. Long-term follow-up study on prevention of aphakic cystoid macular oedema by topical indomethacin. Br J Ophthalmol 1980; 64: 324-8
72. Ambache N, Kavanagh L, Whiting J. Effect of mechanical stimulation on rabbits' eyes: release of active substance in anterior chamber perfusates. J Physiol 1965; 176: 378-408
73. Anggard E. Samuelsson B. Smooth muscle stimulating lipids in sheep iris: the identification of prostaglandin F2 alpha. Prostaglandins and related factors 21. Biochem Pharmacol 1964; 13: 281-3
74. Cole DF, Unger WG. Prostaglandins as mediator for the responses of the eye to trauma. Exp Eye Res 1973; 17: 357-68
75. Waitzman MB, King CD. Prostaglandin influences on intra ocular pressure and pupil size. Am J Physiol 1967; 212: 329-34
76. Roberts CW. A comparison of diclofenac sodium to flurbiprofen for maintaining intraoperative mydriasis. Invest Ophthalmol Vis Sci 1993; 35: 1967
77. Solomon KD, Turkalj JW, Whiteside SB, et al. Topical 0.5% ketorolac vs 0.03 flurbiprofen for inhibition of miosis during cataract surgery. Arch Ophthalmol 1997; 115: 1119-22
78. Roberts CW. Comparison of diclofenac sodium and flurbiprofen for inhibition of surgically induced miosis. J Cataract Refract Surg 1996; 22 Suppl. 1: 780-7
79. Stewart R, Grosserode R, Cheetham JK, et al. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Clin Ther 1999; 21: 723-32
80. Cillino S, Casanova F, Cucco F, et al. Topical flurbiprofen in extracapsular cataract surgery: effect on pupillary diameter and iris fluoresin leakage. J Cataract Refract Surg 1993; 19: 622-5
81. Colin J, Paquette B. Comparison of the analgesic efficacy of nepafenac ophthalmic suspension compared to diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase 2, randomized, double-masked trial. Clin Ther 2006; 28 (4): 527-36
82. Yee RW, the Ketorolac Radial Keratotomy Study Group. Analgesic efficacy and safety of nonpreserved ketorolac tromethamine ophthalmic solution following radial keratotomy. Am J Ophthalmol 1998; 125: 472-80
83. Solomon KD, Donnenfeld ED, Raizman M, et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg 2004; 30: 1653-60
84. Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Cur Med Res Opin 2004; 20: 2015-9
85. Goyal R, Shankar J, Fone DL, et al. Randomized controlled trial of ketorolac in the management of corneal abrasions. Acta Ophthalmol Scand 2001; 79: 177-9
86. Kaiser PK, Pineda R, Corneal abrasion patching study group. A study of topical nonsteroidal anti-inflammatory drops and no pressure patching in the treatment of corneal abrasions. Ophthalmology 1997; 104: 1353-9
87. Sher NA, Frantz JM, Talley A, et al. Topical diclofenac in the treatment of ocular pain after excimer photorefractive keratectomy. Refract Cornea Surg 1993; 9: 425-36
88. Eiferman RA, Hoffman RS, Sher NA. Topical diclofenac reduces pain following photorefractive keratectomy. Arch Ophthalmol 1993; 111: 1022
89. Szerenyi K, Sorken K, Garbus JJ, et al. Decrease in normal human corneal sensitivity with topical diclofenac sodium. Am J Ophthalmol 1994; 118: 312-5
90. Donshik PC, Pearlman D, Pinnas J, et al. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastin 0.05%: a mulcenter comparison in patients with seasonal allergic conjunctivitis. Adv Ther 2000; 17: 94-102
91. Laibovitz RA, Koester J, Schaich L, et al. Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 1995; 11: 361-8
92. Wood TS, Stewart RH, Bowman RW, et al. Suprofen treatment of contact ICNS-associated giant papillary conjunctivitis. Ophthalmology 1988; 95: 822-6
93. Tauber J, Raizman MB, Ostrov CS, et al. A multi-center comparison of the ocular safety and efficacy of diclofenac sodium 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Therp 1998; 14: 137-45
94. Ciprandi G, Buscaglia S, Cerqueti MP, et al. Topical anti-inflammatory drugs in the treatment of allergic pollinosic conjunctivities: a comparative double-blind study. J Invest Allergol Clin Immunol 1992; 2 (5): 248-52
95. Frucht-Perry J, Siganos CS, Solomon A, et al. Topical indomethacin solution versus dexamethasone solution for treatment of inflamed pterygium and pinguecula: a prospective randomized clinical study. Am J Ophthalmol 1999; 127: 148-52
96. Goethals M, Missotten L. Efficacy and safety of indomethacin 0.1% versus flurbiprofen 0.03% eye drops in inflammation after argon laser trabeculoplasty. Doc Ophthalmol 1994; 85: 287-93
97. Kent AR, Dubiner HB, Whitaker R, et al. The safety and efficacy of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-C. Opthalmic Surg Lasers 1998; 29: 562-9
98. Apt L, Voo I, Isenberg SJ. A randomized clinical trial of the non-steroidal eye drop diclofenac after strabismus surgery. Ophthalmology 1998; 105: 1449-52
99. Rajpal RK, Cooperman BB. Analgesic efficacy and safety of ketorolac after photorefractive keratectomy. J Refract Surg 1999; 15: 661-7
100. Costagliola C, Parmeggiani F, Antinozzi PP, et al. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timlol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp Eye Res 2005; 81: 610-5
101. Koevary SB. Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metabol 2003; 4: 213-22
102. Song Q, McCollum GW, Macrorie-Fairweather R, et al. Nepafenac metabolite, amfenac, inhibits VEGF induced phosphorylation of ERK in human retinal microvascular endothelial cells [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 4204
103. Souza Filho JP, Correa ZM, Marshall JCA, et al. The effect of a selective cyclooxygenase-2 (COX-2) inhibitor on the proliferative rate of retinoblastoma cell lines [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 3418
104. Caissie AL, Marshall JCA, Odashiro AN, et al. The cyclooxygenase-2 inhibitor nepafenac improves the function of macrophages suppressed by uveal melanoma conditioned medium [abstract]. Invest Ophthalmol Vis Sci 2005; 46 Suppl.: 3407
105. Nguyen KD, Lee DA. Effects of steroids and nonsteroidal antiinflammatory agents on human ocular fibroblast. Invest Ophthalmol Vis Sci 1992; 33: 2693-701
106. Nguyen KD, Lee DA. In vitro evaluation of antiproliferative potential of topical cyclo-oxygenase inhibitors in human Tenon's fibroblasts. Exp Eye Res 1993; 57: 97-105
107. Sharir M Exacerbation of asthma by topical diclofenac. Arch Opthalmol 1997; 115:294-5
108. Polachek J, Shvartzman P. Acute bronchial asthma associated with the administration of indomethacin. Isr J Med Sci 1996; 32: 1107-9
109. Sheehan GJ, Kutzner MR, Chin WD. Acute asthma attack due to ophthalmic indomethacin. Ann Intern Med 1989; 111: 337-8
110. Gills JP. Voltaren associated with medication keratitis [letter]. J Cataract Refract Surg 1994; 20: 110
111. Sher NA, Krueger RR, Teal R, et al. Role of topical corticosteroids and nonsteroidal anti-inflammatory drugs in the etiology of stromal infiltrates after excimer photorefractive keratectomy. J Refract Corneal Surg 1994; 10: 587-8
112. Shimazaki J, Saito H, Yang HY, et al. Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eye drops. Cornea 1995; 14: 623-7
113. Guidera AC, Luchs JI, Udell IJ. Keratitis, Ulceration, and perforation associated with topical non-steroidal anti-inflammatory drugs. Ophthalmology 2001; 108: 936-44
114. Congdon NG, Schein OD, van Kulajta P, et al. Corneal complications associated with topical ophthalmic use of nonsteroidal anti-inflammatory drugs. J Cataract Refract Surg 2001; 27: 622-31
115. O'Brien TP, Li QJ, Sauerburger F, et al. The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. Ophthalmology 2001; 108: 656-9
116. Reviglio VE, Rana TS, Li QJ, et al. Effects of topical nonsteroidal antiinflammatory drugs on the expression of matrix metalloproteinases in the cornea. J Cataract Refract Surg 2003; 29: 989-97
117. Asai T, Nakagami T, Mochizuki M, et al. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea 2006; 25: 224-7
118. Mian SI, Gupta A, Pineda R II. Corneal ulceration and perforation with ketorolac tromethamine (Acular®) use after PRK. Cornea 2006; 25: 232-4